Bremelanotide PT-141, or bremelanotide, belongs to the new class of synthetic proteins that work as melanocortin agonists. It is a peptide compound known as Palatin technique after new drug development. Its molecular formula C50H68N14O10, its molecular weight/mass 1,025.2. This new representative of peptides was only recently synthesized from Melanotan-ppeptide, and to date is participating in some clinical trials using animal models in different countries. To date, the largest randomized controlled and double-blind clinical trials were done in 2004 and 2007 with a view to evaluating safety, pharmacokinetic properties and its pharmacodynamics for men and women respectively. At the end of 2012, the second phase of the clinical study was completed and the results will be published shortly. The PT-141 main feature is to have positive influence on sexual systemic dysfunction. Unlike other compounds and hormones, bremelanotide does not affect the vascular system, instead this research compound works by targeting melanocortin receptors, which in turn leads to sexual stimulation and modulation of inflammation.